Form4insider filings, from the source

Company · CIK 0001740547 · SIC 2834 — Pharmaceutical Preparations

Urovant Sciences Ltd. · UROV

Insider activity reported against this company. All insider holders · On EDGAR ↗

1M3M6M1Y2YAll datashares as filed — not split-adjusted
Open-market buys & salesbuys $300.0M · 8sales $0 · 0net $300.0M
$100k$100k$10M$10M$1B$1BbuyssalesSep 30Sep 30Sep 30Oct 1Oct 1Oct 1Oct 2

Reported at this company — common stock

TradeReported (ET)InsiderSharesAvg priceTotalOwned afterΔ stakeFlags
Oct 1, 2018 PForm 4 →Oct 3, 7:18 pm EDTAndrew Lo10% Owner2,678,571$14.00$37,499,99422,703,669+13.4% plan?
Oct 1, 2018 PForm 4 →Oct 3, 5:58 pm EDTDexxon Holdings Ltd. +210% Owner2,678,571$14.00$37,499,99422,703,669+13.4% plan?
Oct 1, 2018 PForm 4 →Oct 3, 5:56 pm EDTVIKING GLOBAL INVESTORS LP +610% Owner2,678,571$14.00$37,499,99422,703,669+13.4% plan?
Oct 1, 2018 PForm 4 →Oct 3, 5:52 pm EDTVIKING GLOBAL PERFORMANCE LLC +510% Owner2,678,571$14.00$37,499,99422,703,669+13.4% plan?
Oct 1, 2018 PForm 4 →Oct 3, 5:50 pm EDTQVT Associates GP LLC +110% Owner2,678,571$14.00$37,499,99422,703,669+13.4% plan?
Oct 1, 2018 PForm 4 →Oct 3, 5:47 pm EDTSVF Investments (UK) Ltd +310% Owner2,678,571$14.00$37,499,99422,703,669+13.4% plan?
Oct 1, 2018 PForm 4 →Oct 3, 4:49 pm EDTPatrick Machado10% Owner2,678,571$14.00$37,499,99422,703,669+13.4% plan?
Oct 1, 2018 PForm 4 →Oct 3, 4:48 pm EDTRoivant Sciences Ltd.10% Owner2,678,571$14.00$37,499,99422,703,669+13.4% plan?

Reported at this company — derivatives (options, RSUs, warrants)

TradeReported (ET)InsiderSharesAvg priceTotalOwned afterΔ stakeFlags
Mar 1, 2019 AForm 4 →Mar 5, 8:44 pm ESTJames A. Robinson Jr.Director50,000——50,000—
Jan 6, 2019 AForm 4 →Jan 8, 5:24 pm ESTMichael E. McFaddenCCO/Urovant Sciences, Inc.100,000——100,000—
Jan 6, 2019 AForm 4 →Jan 8, 5:23 pm ESTBryan E. SmithGC/Urovant Sciences, Inc.70,000——70,000—
Jan 6, 2019 AForm 4 →Jan 8, 5:22 pm ESTKeith KatkinPEO;CEO/Urovant Sciences, Inc., Director350,250——350,250—
Jan 6, 2019 AForm 4 →Jan 8, 5:22 pm ESTChristine OcampoPFAO;CAO/Urovant Sciences, Inc70,000——70,000—
Jan 6, 2019 AForm 4 →Jan 8, 5:21 pm ESTCornelia Haag-MolkentellerCMO/Urovant Sciences, Inc.100,000——100,000—
Jan 6, 2019 AForm 4 →Jan 8, 5:20 pm ESTNori EbersoleSVP;CHRO/Urovant Sciences, Inc65,000——65,000—
Nov 21, 2018 AForm 4 →Nov 26, 8:40 pm ESTFrank TortiDirector50,000——50,000—
Nov 21, 2018 AForm 4 →Nov 26, 8:40 pm ESTMyrtle S PotterDirector50,000——50,000—
Nov 21, 2018 AForm 4 →Nov 26, 8:38 pm ESTPierre LegaultDirector36,650——36,650—
Nov 21, 2018 AForm 4 →Nov 26, 8:37 pm ESTSef KurstjensDirector36,650——36,650—
Oct 15, 2018 AForm 4 →Oct 17, 6:12 pm EDTKeith KatkinPEO;CEO-Urovant Sciences,Inc., Director99,967——99,967—
Oct 15, 2018 AForm 4 →Oct 17, 6:11 pm EDTNori EbersoleSVP&CHRO-Urovant Sciences,Inc.3,000——3,000—
Oct 15, 2018 AForm 4 →Oct 17, 6:10 pm EDTBryan E. SmithGC of Urovant Sciences,Inc.3,500——3,500—
Oct 15, 2018 AForm 4 →Oct 17, 6:09 pm EDTCornelia Haag-MolkentellerCMO of Urovant Sciences, Inc.1,000——1,000—
Oct 15, 2018 AForm 4 →Oct 17, 6:08 pm EDTMichael E. McFaddenCCO of Urovant Sciences, Inc.4,750——4,750—
Oct 15, 2018 AForm 4 →Oct 17, 6:07 pm EDTChristine OcampoPFAO;CAO/Urovant Sciences,Inc.3,750——3,750—
Oct 1, 2018 AForm 4 →Oct 3, 9:04 pm EDTKeith KatkinPEO;CEO-Urovant Sciences,Inc., Director200,250——200,250—
Sep 26, 2018 AForm 4 →Sep 28, 4:10 pm EDTKeith KatkinPEO;CEO-Urovant Sciences,Inc., Director39,815——39,815—